Evofem Biosciences, Inc. Cash And Cash Equivalents At Carrying Value

Quick Answer

Evofem Biosciences, Inc. reported Cash And Cash Equivalents At Carrying Value of $2.77 million for the year ending 2022.

  • Evofem Biosciences, Inc. showed a decrease of -64.2% in Cash And Cash Equivalents At Carrying Value from 2021 to 2022.
  • This data is from Evofem Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 27, 2024.
  • XBRL data for this metric is available from 2012 to 2022 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 11 years of available data (2012 to 2022), Evofem Biosciences, Inc.'s Cash And Cash Equivalents At Carrying Value has declined by 75.1%.
  • Historical annual values: Fiscal year 2022: $2.77 million | Fiscal year 2021: $7.73 million | Fiscal year 2020: $48.89 million | Fiscal year 2019: $15.57 million | Fiscal year 2018: $1.33 million | Fiscal year 2017: $1.21 million | Fiscal year 2016: $11.48 million | Fiscal year 2015: $37.75 million | Fiscal year 2014: $75.95 million | Fiscal year 2013: $4.36 million | Fiscal year 2012: $11.10 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: